Atlas Trials

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Clinical trial NCT01092585 · UNKNOWN

Trial details

NCT number
NCT01092585
Sponsor
Genta Incorporated
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Melanoma
Start date
2010-02-01
Primary completion
2012-03-01
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.